-+ 0.00%
-+ 0.00%
-+ 0.00%

WuXi XDC out-licenses WuXiTecan-2 ADC payload-linker platform to Ona Therapeutics

PUBT·09/17/2026 08:10:27
Listen to the news
WuXi XDC out-licenses WuXiTecan-2 ADC payload-linker platform to Ona Therapeutics
  • WuXi XDC out-licensed its WuXiTecan-2 payload-linker platform to Ona Therapeutics for a single-target antibody-drug conjugate program.
  • Ona received an exclusive global license; WuXi XDC will support CMC development and manufacturing through its ADC CRDMO platform.
  • Deal terms include an upfront payment, development, regulatory, and sales milestones, and tiered royalties on net sales upon commercialization.
  • Partnership marks the companies’ second ADC collaboration, following a 2024 technology-licensing agreement supporting Ona’s pipeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi XDC Cayman Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609170409PR_NEWS_USPR_____CN50550) on September 17, 2026, and is solely responsible for the information contained therein.